Loading
RP
Reata Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Soni Manmeet Singh, was filed 04 Jan 2022.
Reata Pharmaceuticals Inc: what insiders have been doing
Reata Pharmaceuticals Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Reata Pharmaceuticals Inc. The previous disclosure was published on 28 September 2023.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
95
Thresholds
n/a
Buy Volume
€370,476
1 ops. · all time
Sell Volume
€12M
43 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$1.9M
Net income-US$268.5M-14075.0% margin
Last declaration on 28 September 2023
Declarations95 total
31,467 sharesClass A common stockSEC:0000905148-23-001027:0
49,701 sharesClass A common stockSEC:0000899243-23-019545:0
25,004 sharesClass A common stockSEC:0000905148-23-001010:0
379,281 sharesClass A common stockSEC:0000899243-23-019543:0
5,565 sharesClass A common stockSEC:0000899243-23-019544:0
33,805 sharesClass A common stockSEC:0000899243-23-019542:0
62,621 sharesClass A common stockSEC:0000899243-23-019540:0
6,116 sharesClass A common stockSEC:0000899243-23-019533:0
24,089 sharesClass A common stockSEC:0000899243-23-019532:0
6,017 sharesClass A common stockSEC:0000899243-23-019534:0
10,907 sharesClass A common stockSEC:0000899243-23-019536:0
28,416 sharesClass A common stockSEC:0000899243-23-019541:0
7,359 sharesClass A common stockSEC:0000899243-23-019539:0
81,633 sharesClass A common stockSEC:0000899243-23-019538:0
122,480 sharesClass A common stockSEC:0000899243-23-019535:0
45,000 sharesClass A common stockSEC:0000899243-23-019537:0
3,175 shares@ US$172.025435.4% of flowClass A common stockSEC:0001209191-23-049792:0
406 shares@ US$169.2022.1% of flowClass A common stockSEC:0001209191-23-048601:0
500,000 shares0Class A common stockSEC:0000899243-23-018374:0
2,144 shares@ US$169.068745.5% of flowClass A common stockSEC:0001209191-23-046294:0
193 shares@ US$169.05510.3% of flowClass A common stockSEC:0001209191-23-046276:0
1,755 shares@ US$168.41359.8% of flowClass A common stockSEC:0001209191-23-046306:0
807 shares@ US$169.03671.8% of flowClass A common stockSEC:0001209191-23-046282:0
807 shares@ US$169.039330.8% of flowClass A common stockSEC:0001209191-23-046318:0
1,250 shares@ US$92.2053.8% of flowClass A common stockSEC:0001209191-23-044004:0
25 of 95 declarations
About Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company that was historically listed on the NASDAQ market in the United States. The company built its reputation on developing therapies for serious and rare diseases with limited or no approved treatment options. Founded in the early 2000s, Reata originally centered its research strategy on cellular pathways involved in metabolism and inflammation, with a strong scientific focus on Nrf2 activation. Its headquarters were in Texas, first in Irving and later in the Dallas/Plano area, reflecting its location in one of the more active U.S. biotech and life-science corridors. Over time, Reata evolved from a purely clinical-stage developer into a company with a commercial asset, while remaining highly dependent on specialty-drug innovation and regulatory execution.
The company’s core business line became the development and commercialization of SKYCLARYS (omaveloxolone), its first approved product. SKYCLARYS is indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older. This approval was strategically important because it transformed Reata from a development-stage biotech into a company with a marketed therapy and a direct commercial footprint. In addition to SKYCLARYS, Reata pursued other programs, including bardoxolone methyl, across indications such as renal, cardiovascular, and pulmonary diseases. These assets expanded the scientific narrative, although they also carried materially higher clinical risk and were more dependent on trial outcomes.
Read moreShow less
From a competitive standpoint, Reata stood out as a focused rare-disease biotechnology company. Its positioning depended less on scale and more on differentiation, regulatory milestones, and clinical value creation in niche therapeutic areas. The approval of SKYCLARYS by the U.S. FDA was a defining moment: it established Reata as the first company to bring an approved therapy to Friedreich’s ataxia, a rare, progressive neurological disease. That milestone improved the company’s market visibility and strengthened its asset quality profile, even though the patient population remained limited and commercialization economics were inherently specialized.
A major recent event was Reata’s acquisition by Biogen, announced in 2023 and completed in September 2023. As a result, Reata no longer operates as an independent public company, but it remains highly relevant for investors reviewing SEC Form 4 insider transactions and the history of the company’s value creation. For French, Belgian, and Swiss investors, Reata is best understood as a U.S. NASDAQ-listed biotech that successfully translated a focused rare-disease R&D platform into an approved product and then became a strategic acquisition target for a larger pharmaceutical group.
